The manufacturer is conducting a mandatory parameter upgrade (P-14.8) based on two Fibrinogen-C reporting issues. Issue number one was a result of 3 customer complaints where low abnormal Fibrinogen sample reports were reporting as normal. Issue two was identified by the manufacturer during R&D where high Fibrinogen samples were reported as low.